Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (41-50 of 194) with videos related to

Pageof 20
Sort By:
Breast (Edinburgh, Scotland)|April 23, 2013
Results and consequence of the systematic staging imaging at the time of the breast cancer diagnosisA Mailliez, A Turpin, P Vennin, et al.
Pharmacoeconomics|December 9, 1995
Quality of life as an outcome in breast cancer. Clinical applicationJ Bonneterre, S Schraub, S Lecomte, et al.
La Revue De Medecine Interne|January 1, 1995
[Immunotherapy of malignant melanoma. New prospects]M Hebbar, L Vanlemmens, S Lecomte, et al.
Lancet (London, England)|April 21, 1984
Aminoglutethimide-induced hypercholesterolaemiaJ Bonneterre, M Nguyen, B Hecquet, et al.
Lille Medical : Journal De La Faculte De Medecine Et De Pharmacie De L'Universite De Lille|June 1, 1979
[Cis-DDP (cis-diaminodichloroplatinum II) in the treatment of solid tumors. Apropos of 28 cases]L Adenis, P Cappelaere, D Vallet, et al.
Lancet (London, England)|August 5, 1995
Docetaxel-induced alopecia can be preventedM Lemenager, C Genouville, E H Bessa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study GroupM Clavel, J Bonneterre, H d'Allens, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patientsF Revillion, M Hebbar, J Bonneterre, et al.
Pathologie-Biologie|April 1, 1996
[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer]T Soussi, J P Peyrat, R Lubin, et al.
Bulletin Du Cancer|January 1, 1997
[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France]J P Peyrat, P Vennin, L Hornez, et al.
Pageof 20

Showing results (41-50 of 194) with videos related to

Sort By:
Pageof 20
Breast (Edinburgh, Scotland)|April 23, 2013
Results and consequence of the systematic staging imaging at the time of the breast cancer diagnosisA Mailliez, A Turpin, P Vennin, et al.
Pharmacoeconomics|December 9, 1995
Quality of life as an outcome in breast cancer. Clinical applicationJ Bonneterre, S Schraub, S Lecomte, et al.
La Revue De Medecine Interne|January 1, 1995
[Immunotherapy of malignant melanoma. New prospects]M Hebbar, L Vanlemmens, S Lecomte, et al.
Lancet (London, England)|April 21, 1984
Aminoglutethimide-induced hypercholesterolaemiaJ Bonneterre, M Nguyen, B Hecquet, et al.
Lille Medical : Journal De La Faculte De Medecine Et De Pharmacie De L'Universite De Lille|June 1, 1979
[Cis-DDP (cis-diaminodichloroplatinum II) in the treatment of solid tumors. Apropos of 28 cases]L Adenis, P Cappelaere, D Vallet, et al.
Lancet (London, England)|August 5, 1995
Docetaxel-induced alopecia can be preventedM Lemenager, C Genouville, E H Bessa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study GroupM Clavel, J Bonneterre, H d'Allens, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patientsF Revillion, M Hebbar, J Bonneterre, et al.
Pathologie-Biologie|April 1, 1996
[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer]T Soussi, J P Peyrat, R Lubin, et al.
Bulletin Du Cancer|January 1, 1997
[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France]J P Peyrat, P Vennin, L Hornez, et al.
Pageof 20